Список литературы к Главе 17

94. Dussadee K. et al. Incidence and risk factors of relapses in idiopathic autoimmune hemolytic anemia // J. Med. Assoc. Thai. 2010. Vol. 93, suppl. 1. P. S165–S170.

95. Lechner K., Jäger U. How I treat autoimmune hemolytic anemias in adults // Blood. 2010. Vol. 116, N 11. P. 1831–1838.

96. Birgens H. et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia // Br. J. Haematol. 2013. Vol. 163, N 3. P. 393-399.

97. Michel M. et al. A randomized and double­blind controlled trial evaluating the safety and efficacy of rituximab for warm auto­immune hemolytic anemia in adults (the RAIHA study) // Am. J. Hematol. 2017. Vol. 92, N 1. P. 23–27.

98. D’Arena G. et al. Rituximab therapy for chronic lymphocytic leukemia­associated autoimmune hemolytic anemia // Am. J. Hematol. 2006. Vol. 81, N 8. P. 598–602.

99. Zaja F. et al. Anti­CD20 therapy for chronic lymphocytic leukemia­associated autoimmune diseases // Leuk. Lymphoma. 2003. Vol. 44, N 11. P. 1951–1955.

100. Kaufman M. et al. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia // Leuk. Lymphoma. 2009. Vol. 50, N 6. P. 892–899.

101. Rossignol J. et al. Rituximab­cyclophosphamide­dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia // Leukemia. 2011. Vol. 25, N 3. P. 473–478.

102. Bowen D.A. et al. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone // Leuk. Lymphoma. 2010. Vol. 51, N 4. P. 620-627.

103. Nikitin E. et al. Ibrutinib plus rituximub in steroid refractory autoimmune hemolytic anemia: elaboration of treatment approach (Israel): an interim analysis of the ROHS trial: PS1158 // HemaSphere. 2019. Vol. 3. P. 525–526.

104. Osterborg A., Karlsson C., Lundin J. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia // Curr. Hematol. Malig. Rep. 2009. Vol. 4, N 1. P. 47–53.

105. Zent C.S., Kay N.E. Autoimmune complications in chronic lymphocytic leukaemia (CLL) // Best Pract. Res. Clin. Haematol. 2010. Vol. 23, N 1. P. 47–59.

106. Карагюлян С.Р., Шавлохов В.С., Галузяк В.С., Шулутко Е.М., Звонков Е.Е. Хирургические вмешательства у больных старших возрастных групп при заболеваниях системы крови // Гериатрическая гематология. 2007. № 5. С. 48–55.

107. Moyo V.M. et al. High­dose cyclophosphamide for refractory autoimmune hemolytic anemia // Blood. 2002. Vol. 100, N 2. P. 704–706.

108. Аксельрод Б.А., Балашова Е.Н., Баутин А.Е., Баховадинов Б.Б., Бирюкова Л.С., Буланов А.Ю. и др. Клиническое использование эритроцитсодержащих компонентов донорской крови // Гематология и трансфузиология. 2018. Т. 63, № 4. С. 372–435.

109. McLeod B.C. Evidence based therapeutic apheresis in autoimmune and other hemolytic anemias // Curr. Opin. Hematol. 2007. Vol. 14, N 6. P. 647–654.

110. Szczepiorkowski Z.M. et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidence­based approach from the Apheresis Applications Committee of the American Society for Apheresis // J. Clin. Apheresis. 2010. Vol. 25, N 3. P. 83–177.

111. Neave L. et al. Severe refractory idiopathic warm autoimmune haemolytic anaemia responsive to complement inhibition with eculizumab // BMJ Case Rep. 2018. Vol. 11, N 1. Article ID e226429.

112. Barcellini W. New insights in the pathogenesis of autoimmune hemolytic anemia // Transfus. Med. Hemother. 2015. Vol. 42, N 5. P. 287–293.

113. Salama A. et al. The effect of erythropoiesis­stimulating agents in patients with therapy­refractory autoimmune hemolytic anemia // Transfus. Med. Hemother. 2014. Vol. 41, N 6. P. 462–468.

114. D’Arena G. et al. Chronic lymphocytic leukemia­associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients // Eur. J. Haematol. 2010. Vol. 85, N 6. P. 502–507.

115. Bussel J.B. et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double­blind, placebo­controlled trial // Lancet. 2009. Vol. 373, N 9664. P. 641–648.

116. D’Arena G., Cascavilla N. Romiplostim for chronic lymphocytic leukemia­associated immune thrombocytopenia // Leuk. Lymphoma. 2011. Vol. 52, N 4. P. 701–704.

117. Gudbrandsdottir S., Frederiksen H., Hasselbalch H. Thrombopoietin­receptor agonists in haematological disorders: the Danish experience // Platelets. 2012. Vol. 23, N 6. P. 423–429.

118. Koehrer S., Keating M.J., Wierda W.G. Eltrombopag, a second­generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia­associated ITP // Leukemia. 2010. Vol. 24, N 5. P. 1096–1098.

119. Рахмани А.Ф., Михайлова Е.А., Дубинкин И.В. Тактика трансфузионной терапии концентратами тромбоцитов у больных с депрессиями кроветворения // Гематология и трансфузиология. 2017. Т. 62, № 4. С. 218–222.

120. Chikkappa G. et al. Cyclosporine and prednisone therapy for pure red cell aplasia in patients with chronic lymphocytic leukemia // Am. J. Hematol. 1992. Vol. 41, N 1. P. 5–12.

121. Gotic M. et al. Successful treatment of refractory pure red cell aplasia secondary to chronic lymphocytic leukaemia with cyclosporine A: correlation between clinical and in vitro effects // Nouv. Rev. Fr. Hematol. 1994. Vol. 36, N 4. P. 307–309.

122. Pantelidou D. et al. Anti­CD20 monoclonal antibody rituximab for the treatment of B­cell chronic lymphocytic leukemia­associated pure red cell aplasia // Hematol. J. 2004. Vol. 5, N 6. P. 546–547.

123. Narra K. et al. Pure red cell aplasia in B­cell lymphoproliferative disorder treated with rituximab: re­ port of two cases and review of the literature // Leuk. Res. 2006. Vol. 30, N 1. P. 109–114.

124. Ru X., Liebman H.A. Successful treatment of refractory pure red cell aplasia associated with lymph­oproliferative disorders with the anti­CD52 monoclonal antibody alemtuzumab (Campath­1H) // Br. J. Haematol. 2003. Vol. 123, N 2. P. 278–281.

125. Rodon P., Breton P., Courouble G. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath­1H // Eur. J. Haematol. 2003. Vol. 70, N 5. P. 319–321.

126. Goldschmidt N., Rund D. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib // Leuk. Lymphoma. 2017. Vol. 58, N 2. P. 498–500.

127. Dmitrieva E.A. et al. Infections in chronic lymphocytic leukemia patients treated with ibrutinib: incidence and predisposing factors // Clin. Oncohematol. 2019. Vol. 12. P. 438–448.